SCHEMBL4526704

SCHEMBL4526704

COc1ccccc1SC(C(=O)NO)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
TDP1 Q9NUW8 1/20 0.56
LMNA P02545 5/20 0.48
ALDH1A1 P00352 4/20 0.48
NPSR1 Q6W5P4 2/20 0.48
PCTP Q9UKL6 2/20 0.48
STARD10 Q9Y365 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HTT P42858 1/20 0.48
ADAM17 P78536 2/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4537378 0.85 MAPT (0.61) MAPTTDP1LMNAALDH1A1NPSR1
SCHEMBL8119303 0.82 EPHX1 (0.50) MAPTTDP1LMNAALDH1A1NPSR1
SCHEMBL4536717 0.81 LMNA (0.50) MAPTTDP1LMNAALDH1A1NPSR1
SCHEMBL7617760 0.81 POLB (0.47) MAPTTDP1LMNAALDH1A1SMN1; SMN2
SCHEMBL4538140 0.80 LMNA (0.57) MAPTTDP1LMNAALDH1A1NPSR1
SCHEMBL4536066 0.78 LMNA (0.48) MAPTTDP1LMNAALDH1A1NPSR1
SCHEMBL4538082 0.78 HDAC4 (0.47) MAPTTDP1LMNAALDH1A1NPSR1
SCHEMBL4540175 0.78 LMNA (0.48) MAPTTDP1LMNAALDH1A1NPSR1
SCHEMBL4540028 0.77 LMNA (0.47) MAPTTDP1LMNAALDH1A1SMN1; SMN2
SCHEMBL4534294 0.77 ADAM17 (0.66) MAPTTDP1LMNAALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 MAPT 1533/4885TDP1 795/4885LMNA 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.